Questões de Concurso

Foram encontradas 685 questões

Resolva questões gratuitamente!

Junte-se a mais de 4 milhões de concurseiros!

Q2242136 Inglês
The hard cell

The hard cell Thanks to politics, stem cell research in the United States is suffering. But not so in Sweden, which is poised to capture what could be the biggest new market to hit biotech in a decade.

By Stephan Herrera
February 13, 2003

New York, January 1, 2006:
Sweden announces that one of its biotechnology companies is the first in the world to enter clinical trials with a new drug that could cure Alzheimer's disease. Four years ago this type of research was all but stopped in the United States by political and ethical questions − which is ...61... Sweden now seems in the best position to capture a $25 billion market.

      Any day now, the U.S. Congress is expected to pass a sweeping new law that could dramatically inhibit researchers from working with stem cells taken from human embryos. Such cells, which can be used to grow a whole host of new cells and organs, could fundamentally change the way we treat heretofore intractable maladies like Alzheimer's disease, Parkinson's disease, cancer, stroke, liver failure, and heart disease. The only problem is that these cells by definition are derived from human embryos, many of which are cloned or come from unused fetuses collected at fertility clinics. The argument, from a certain segment of the American political spectrum, is that ....62... methods are morally wrong. They are ....63... a form of abortion or an activity that could eventually lead to human cloning.

      Those working in stem cell research say the short-term effect of the legislation will be to further chill all forms of scientific inquiry and commercialization efforts in the field. Entrepreneurs and investors are already eschewing such research − in large part because of the additional uncertainty and risk that politics introduce.

      Of the nearly 50 private stem cell companies in the United States, only a handful are still viable. Meanwhile, across the Atlantic, Sweden has avoided many of the political and ethical quagmires surrounding this type of research. It currently has 40 private stem cell companies, a number that's growing. Sweden's leading research universities have 32 percent of the world's stem cell inventory, close on the heels of the United States' 35 percent.

        Sweden, say analysts, is now in the best position to capture a worldwide market for drugs based on stem cell therapies that could grow to $25 billion in the next three to five years − nearly equal to the whole biotech industry at present. This estimate doesn't even address the market for stem cells capable of repairing damaged vital organs like the brain, heart, and kidneys. If the United States offers an object lesson of what can happen when scientific inquiry and investment capital fall victim to politics, Sweden and its leading stem cell startup, NeuroNova, offer the opposite example. How odd that the United States, which for generations has been the envy of the world for its progressive views of science and commercialization, should now have a biomedical climate chillier than a Swedish winter.

       One company feeling a lot of pain is StemCells, which at first glance seems to have it all: founding scientists include Stanford's Dr. Weissman and Fred Gage of the Salk Institute in La Jolla, California. An equally well-regarded expert in the treatment of Alzheimer's, Dr. Gage spent five years in Sweden as a researcher and now sits on a national committee on stem cell research there. The firm's chairman is Roger Perlmutter, Amgen's head of research.

    Yet over the past two years, none of management's efforts to help investors and even critics reconsider the stem cell field have worked. At press time, the stock was thinly traded and sitting in the neighborhood of 50 cents. With less than $15 million in cash, the company likely won't exist at this time next year. (CEO Martin McGlynn, who joined the firm in January 2001, would not talk to Red Herring, despite repeated efforts.)

      Some observers on Wall Street are asking, If StemCells can't make it, who can? Geron, the only other publicly held stem cell firm to speak of, is in a fix, too. The company's stock price is also moribund, at $3.85 per share. Thanks to some capital infusions a few years ago, when money came easy, Geron still has $40 million on hand, but by the end of next year, that too will likely be gone. Once a media darling, Geron focuses on diagnostic tests and drugs derived from stem cells, a strategy that's not going well. For the nine months ended last September, revenue fell 68 percent to $955,000 and net loss widened 18 percent to $26.7 million. The company's financials were also hit hard after it terminated an agreement with Pharmacia and acquired research technology from Lynx Therapeutics, which Geron bought in a desperate attempt to be seen as something more than just a stem cell company.

     The situation is quite different, however, for Sweden's NeuroNova, which has 30 academic partners and a staff of 20. NeuroNova is working on ways to inject stem cells into the human brain to trigger a process called neurogenesis (the growth of new neural cells), which could combat diseases like Parkinson's, Alzheimer's, and even schizophrenia.

       If NeuroNova is the first to develop a drug capable of treating one of several central nervous system disorders − by far the most lucrative after heart disease products − it will have done so not because it raised more money or got more media buzz than the rest. It will have succeeded because the science is solid, and academe, government, and the investment community are supportive. Meanwhile, the United States will look on with envy and wonder how it, a country known for its entrepreneurial innovation, ever got so short-sighted.

(Adapted from
http://www.redherring.com/investor/2003/02/biotech021303.html)

Instruções: Para responder a questão, assinale, na folha de respostas, a letra correspondente a alternativa que preenche corretamente a lacuna do texto apresentado.
Alternativas
Q2242132 Inglês
From the IPO to the First Trade: Is Underpricing Related to the Trading Mechanism?

Sonia Falconieri, Albert Murphy and Daniel Weaver

        As documented by a vast empirical literature, IPOs are characterized by underpricing. Most of the theoretical literature has linked the size of underpricing to the IPO procedure used on the primary market. In this paper, by using a matched sample of NYSE and Nasdaq IPOs, we show that the size of underpricing also depends on the trading method used in the IPO aftermarket.

         There are two major methods of opening trading of initial public offerings (IPOs) in the U.S. The NYSE is an order-driven market ....56... a call auction allows supply and demand to be aggregated (at one location) prior to the start of trading. .....57.... , Nasdaq is a quote-driven market. Dealers can only specify their best quotes, and participants have KK 58 idea of supply and demand away from the inside quotes.

      We propose a new proxy for ex ante uncertainty of firm value and test it. Our results show that there is a larger level of uncertainty at the beginning of trading on Nasdaq than on the NYSE. This in turn is associated with larger levels of underpricing for Nasdaq IPOs. We suggest that this may be due to the different informational efficiency of the two trading systems.

(http://www.nyse.com/marketinfo/p1020656068262.html?displayPage=%
2Fmarketinfo%2Fmarketinfo.html)
Instruções: Para responder à questão, assinale, na folha de respostas, a letra correspondente à alternativa que preenche corretamente a lacuna do texto apresentado.
Alternativas
Q2239810 Inglês
Text 2A7

       Artificial intelligence (AI) is arguably the most rapidly advancing technology humans have ever developed. A year ago, you wouldn’t often hear AI come up in a regular conversation, but today it seems there’s constant talk about how generative AI tools like ChatGPT and DALL-E will affect the future of work, the spread of information, and more. A major question that has thus far been almost entirely unexamined is how this AI-dominated future will affect people’s minds.

         There’s been some research into how using AI in their jobs will affect people mentally, but there isn’t yet an understanding of how simply living amongst so much AI-generated content and systems will affect people’s sense of the world. How is AI going to change individuals and society in the not-too-distant future?

          AI will obviously make it easier to produce disinformation. That will affect people’s sense of trust as they’re scrolling on social media. AI can also allow someone to imitate your loved ones, which further erodes people’s general ability to trust what was once unquestionable.


Internet: < wired,com > (adapted).  
In the context of the first sentence of the second paragraph of text 2A7, the word “ understanding ” is grammatically classified as 
Alternativas
Q2238992 Inglês
Text 2A7

         Artificial intelligence (AI) is arguably the most rapidly advancing technology humans have ever developed. A year ago, you wouldn’t often hear AI come up in a regular conversation, but today it seems there’s constant talk about how generative AI tools like ChatGPT and DALL-E will affect the future of work, the spread of information, and more. A major question that has thus far been almost entirely unexamined is how this AI-dominated future will affect people’s minds.
           
           There’s been some research into how using AI in their jobs will affect people mentally, but there isn’t yet an understanding of how simply living amongst so much AI-generated content and systems will affect people’s sense of the world. How is AI going to change individuals and society in the not-too-distant future?

            AI will obviously make it easier to produce disinformation. That will affect people’s sense of trust as they’re scrolling on social media. AI can also allow someone to imitate your loved ones, which further erodes people’s general ability to trust what was once unquestionable.

Internet: <wired.com> (adapted). 
In the context of the first sentence of the second paragraph of text 2A7, the word “understanding” is grammatically classified as 
Alternativas
Q2231441 Inglês
(§1º)Budelli Island is part of the La Maddalena Archipelago and is home to Spiaggia Rosa - a stretch of pink sand that's been protected by the Italian government since 1992.

(§2º)The pink shade is caused by the crushed shells of a micro-organism mixing with the sand when it dies. But when the beach started to lose its rose-tinted hue because of over-tourism, visitors were banned in a bit to protect the pink sand.

(§3º)The colour has since returned but a new wave of unauthorised daytrippers are threatening the pink shores. While it is strictly forbidden to step foot on the beach, holidaymakers are able to admire the pink sand from the safety of a boat. But according to one expert, some holidaymakers are flouting the ban.

(§4º)In an article in the Times, Fabrizio Fonnesu, director of the Maddalena archipelago national park said: "The beach is again in danger as people arrive by boat, clamber up the beach, then post photos, which allow us to fine them up to 500 euros (£430)."

(§5º)Tourists who've attempted to take Sardinia's pink sand away as a souvenir can up fined up to 3,500 euros (£3,007). And according to the Guardian, a couple were fined 1,000 euros (£860) in 2001 after they were caught filling a plastic bottle with sand.

(§6º)Brits who want to visit the island will need to book themself onto a private boat tour or a ferry service to glimpse this secluded spot from afar. Other beaches on the island have also brought in measures to minimise the impact of tourists. Only 1,600 people can visit Cala Sisine while Santa Maria Navarrese only permits 1,300 euros.

(§7º)Fewer still are able to visit Cala Mariolu, with only 550 people allowed in per day and each having to pay a 1 euro fee. Elsewhere, Pelosa Beach has banned towels and asked visitors to instead bring mats which gather less sand. Anyone visiting will have to pay 3.50 euros.

(§8º)Meanwhile, tourists wanting to visit the beaches of Cala Coticcio and Cala Brigantina in the archipelago of La Maddalena will have to pay 3 euros per person for access each day after new rules were brought in. The archipelago itself is a national park and only accessible with a guide, which will cost 25 euros for five hours.

(§9º)And anyone caught visiting the archipelago without a guide could face prosecution. Just 60 people will be permitted on each beach per day, as the local authorities look at ways to protect the sites from the impact of tourism.

(§10º)Slots must be booked in advance by contacting a local guide but it is hoped that an app will be launched soon. Here are several other pink beaches holidaymakers can visit across Europe - and one's in the UK. And a beach in the Canary Islands even has sand that looks like popcorn, due to the shape of the coral.

itssfnneed
w.thesun.co.uk/travel/22667535/pink-beach-italy-bundelli-tourists-fined/
Identify the grammatical class of the word "unauthorised" (§3º) in the text: 
Alternativas
Respostas
86: D
87: E
88: D
89: C
90: A